Diray-Arce J, Chang AC, Moradipoor S, Amodio D, Carleton B, Chang WC, Crawford NW, Karoly M, Hoch A, McEnaney K, Kafil TS, Donthireddy M, Steltz SK, van Haren SD, Angelidou A, Smolen KK, Steen H, Lasky-Su J, Tran H, Liu P, Creech CB, Cutland CL, Petousis-Harris H, Nazy I, Yeung RSM, Kochhar S, Black S, Wood N, Nordenberg D, Palma P, Ovsyannikova IG, Kennedy RB, Poland GA, Ozonoff A, Chen RT, Levy O, Top KA
Vaccine. 2025;62
The International Network of Special Immunization Services (INSIS) was established to investigate the causes and risk factors of rare adverse events following immunizations (AEFIs) and develop immunization strategies for mitigating or preventing risk for individuals with prior AEFIs or at risk of AEFIs. INSIS integrates clinical data with multi-omic technologies (e.g., transcriptomics, proteomics, metabolomics) through a global consortium of clinical networks, leading immunology, pharmacogenomics teams to uncover the molecular mechanisms behind AEFIs. The network ensures accurate and standardized data collection and analysis through rigorous data management and quality assurance processes. INSIS also implements harmonized case definitions and protocols for collecting data and samples related to rare AEFIs, such as myocarditis, pericarditis, and Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) after COVID-19 vaccinations. This protocol outlines the comprehensive approach to enhance risk-benefit assessments of vaccines across populations, identify actionable biomarkers to inform discovery and development of safe vaccines, and support personalized vaccination strategies.
